Get started
Work

Superficial basal cell carcinoma treated with curettage followed by topical imiquimod cream: A retrospective study

Year: 2023
Type: article
Abstract: To the Editor: Basal cell carcinoma (BCC) is the most common skin cancer worldwide; up to 30% are the superficial subtype (sBCC), representing a substantial tumor burden.1 It has been reported that curettage followed by daily topical application of imiquimod 5% cream for 6 weeks for a group of patients with either superficial or nodular BCC had no observed recurrences, though follow up was limited to only 12 months.2,3 We have found this treatment effective, and desired to determine the long-term recurrence rates for the sBCC subtype in a group of patients large enough to stratify outcomes by tumor location and average length of treatment required to reach a typical clinical response to imiquimod cream in this setting.
DOI: 10.1016/j.jdin.2023.08.017
Authors: Andrew L. Ondo, James D. Kerner, Isaac P. Ondo, Jacob V. Kerner, Hossein Mousavi, Patrick Trainor, Stuart D. Shanler
Institutions: University of New Mexico, University of California, Santa Barbara, Museum of New Mexico, Epidemiology in dermatology and evaluation of therapeutics, University of Rochester, New Mexico State University
Language: English
Subfield: Dermatology
Field: Medicine
Open Access status: gold
Estimated APC paid: $2,500
OpenAlex ID: W4386574307
FWCI: 0.266
Cites: 3
Cited by: 1
Related to: 10